A Randomized, Double-Blind, Multicenter Study Comparing a Starting Dose of 100 IU or 200 IU of Recombinant Follicle Stimulating Hormone (Puregon®) in Women Undergoing Controlled Ovarian Hyperstimulation for IVF Treatment

Author： Tan Seang   Child Timothy   Cheung Anthony   Fluker Margo   Yuzpe Albert   Casper Robert   Leung Peter   Cadesky Kenneth   Davis Victoria  

Publisher： Springer Publishing Company

ISSN： 1058-0468

Source： Journal of Assisted Reproduction and Genetics, Vol.22, Iss.2, 2005-02, pp. : 81-88

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization

By The Latin-American Puregon IVF Study Group  

Fertility and Sterility, Vol. 76, Iss. 5, 2001-11 ,pp. : 950-956

Elsevier

Access to resources Recommend Favorite

A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment

By Yong P.Y.K.   Brett S.   Baird D.T.   Thong K.J.  

Fertility and Sterility, Vol. 79, Iss. 2, 2003-02 ,pp. : 308-315

Elsevier

Access to resources Recommend Favorite

A prospective, randomized study to assess the tolerance and efficacy of intramuscular and subcutaneous administration of recombinant follicle-stimulating hormone (Puregon)

By Out H.J.   Reimitz P.E.   Coelingh Bennink H.J.T.  

Fertility and Sterility, Vol. 67, Iss. 2, 1997-02 ,pp. : 278-283

Elsevier

Access to resources Recommend Favorite

Human menopausal gonadotropin and recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles

By van Wely M.   Westergaard L.G.   Bossuyt P.M.M.   van der Veen F.  

Fertility and Sterility, Vol. 80, Iss. 5, 2003-11 ,pp. : 1121-1122

Elsevier

Access to resources Recommend Favorite

A double-blind, randomized, placebo-controlled study to assess the efficacy of ketoconazole for reducing the risk of ovarian hyperstimulation syndrome

By Parsanezhad M.E.   Alborzi S.   Pakniat M.   Schmidt E.H.  

Fertility and Sterility, Vol. 80, Iss. 5, 2003-11 ,pp. : 1151-1155

Elsevier

Access to resources Recommend Favorite